Sustained Activation of Extracellular Signal-regulated Kinase Stimulated by Hepatocyte Growth Factor Leads to Integrin alpha 2 Expression That Is Involved in Cell Scattering*

Chun-Chi Liang and Hong-Chen ChenDagger

From the Department of Zoology, College of Life Sciences, National Chung Hsing University, Taichung 40227, Taiwan, Republic of China

Received for publication, November 27, 2000, and in revised form, March 22, 2001


    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

We have previously shown that hepatocyte growth factor (HGF) selectively increases the expression of integrin alpha 2 in Madin-Darby canine kidney (MDCK) cells. In this study, we have further investigated the signal transduction pathways responsible for the event and its role in HGF-induced cell scattering. We found that the level of integrin alpha 2beta 1 expression induced by HGF correlated with the extent of cell scattering and that a functional blocking antibody against integrin alpha 2 at the concentration of 25 µg/ml partially (40%) inhibited the HGF-induced cell scattering. However, in the presence of the specific phosphatidylinositol 3-kinase inhibitor LY294002 or the selective Src family kinase inhibitor PP1, although cells retained their response to HGF for increasing integrin alpha 2 expression, they failed to scatter, indicating that increased expression of integrin alpha 2 alone is not sufficient for cell scattering. Moreover, epidermal growth factor, which induced a transient (1 h) activation of extracellular signal-regulated kinase (ERK) in MDCK cells, only slightly increased integrin alpha 2 expression and failed to trigger cell scattering. Conversely, HGF induced a sustained (at least 12 h) activation of ERK in the cells. Expression of constitutively active ERK kinase (MEK) in MDCK cells led to increased expression of integrin alpha 2 even in the absence of HGF stimulation. In contrast, expression of ERK phosphatase or dominant negative MEK inhibited HGF-induced integrin alpha 2 expression. Taken together, our results suggest that the increased expression of integrin alpha 2beta 1 by HGF is at least partially required for cell scattering and that the duration of MEK/ERK activation is likely to be a crucial determinant for cells to activate integrin alpha 2 expression and cell scattering.


    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Hepatocyte growth factor (HGF),1 also known as scatter factor, is a multifunctional growth factor that elicits mitogenic, motogenic, and morphogenic activities in various cell types (1). The diverse biological effects of HGF are transmitted through activation of its transmembrane receptor encoded by the c-met proto-oncogene (2, 3). Although a number of growth factors are known to modulate cell motility, HGF is unique because of the intensity with which it stimulates motility and induces the epithelial-mesenchymal (E-M) transition. The scatter response of Madin-Darby canine kidney (MDCK) cells to HGF stimulation has been used extensively as a model to study the E-M transition, characterized by the loss of epithelial polarity, the disruption of E-cadherine-mediated cell-cell adhesions, and the acquisition of a migratory mesenchymal cell phenotype (4-6). Upon HGF stimulation, the scatter of MDCK cells can be visualized first as centrifugal spreading of cell colonies (after 2-4 h) followed by cell-cell dissociation (after 4-6 h) and subsequent cell migration (from 6 h) (4, 7).

Several intracellular signaling pathways have been implicated to act downstream of the HGF receptor to mediate scatter response. For example, both phosphatidylinositol 3-kinase (PI3K) and small GTPase Ras have been shown to be essential for cell dissociation and migration following stimulation of MDCK cells with HGF (4, 5, 8). Although GTP-bound Ras interacts with PI3K and may contribute to its activation (9, 10), recent studies suggested that Ras and PI3K might act on different signal transduction cascades to facilitate HGF-induced cell scattering (6, 11). It has been shown that PI3K acts upstream of Tiam1, an activator of the small GTPase Rac, to modulate both E-cadherine-mediated cell adhesion and cell migration (6). More recently, Zondag et al. (12) showed that the expression of oncogenic Ras permanently suppresses Rac activity through down-regulation of Tiam1 expression, which leads to up-regulation of the Rho activity and the E-M transition of MDCK cells. In addition, inhibition of HGF-induced cell scattering by dominant negative Ras or the specific inhibitor for extracellular signal-regulated kinase (ERK) kinase (MEK) has implicated an essential role for the Ras/ERK cascade in cell scattering (13-15).

Integrin alpha 2beta 1 is known to serve as the major receptor for collagen on MDCK cells (16) and play a crucial role in HGF-elicited cell motility and tubulogenesis (7, 17). We have previously demonstrated that HGF selectively enhances the expression of integrin alpha 2 and to a lesser extent alpha 3 in MDCK cells (7). In this study, we have further investigated the signal transduction pathways responsible for increased integrin alpha 2 expression and its role in HGF-induced cell scattering.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Materials-- Recombinant human HGF and epidermal growth factor (EGF) were purchased from R&D Systems, Inc. Fetal bovine serum and LipofectAMINE Plus were purchased from Life Technologies, Inc. G418, Bisindolylmaleimide, genistein, PD98059, LY294002, cycloheximide, and phorbol-12-myristate-13-acetate (PMA) were purchased from Calbiochem (San Diego, CA). PP1 was purchased from BIOMOL Research Laboratories, Inc. (Plymouth Meeting, PA). EZ-Link sulfo-NHS-biotin and avidin-immobilized agarose beads were purchased from Pierce. The polyclonal (AB1944) and monoclonal (clone P1E6) anti-integrin alpha 2 and the polyclonal anti-integrin beta 1 (AB1952) were purchased from Chemicon (Temecula, CA). The polyclonal anti-ERK (sc-94) was purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). The polyclonal anti-phosphoERK was purchased from New England Biolabs, Inc. (Beverly, MA). The cDNA of human integrin alpha 2 was purchased from the American Type Culture Collection. The plasmids encoding constitutively active MEK1 (S218E/S222E), dominant negative MEK1 (S218A/S222A), and ERK phosphatase HVH2 were kindly provided by Dr. Kun-Liang Guan (University of Michigan, Ann Arbor, MI) and described previously (18, 19).

Cell Culture and Transfections-- MDCK II 3B5 cells were maintained in Dulbecco's Modified Eagle Medium (Life Technologies, Inc.) supplemented with 10% fetal bovine serum and cultured at 37 °C in a humidified atmosphere of 5% CO2 and 95% air atmosphere. To induce cell scattering and analyze the expression of integrin alpha 2, MDCK cells were seeded at 105/60-mm dish and allowed to grow as discrete colonies for 2 days. For HGF stimulation, the culture medium was replaced by fresh medium containing 5% serum and 25 ng/ml HGF. In some experiments, HGF was substituted by EGF (100 ng/ml) or PMA (100 nM). After various times, the morphology of cell colonies were photographed under a phase contrast microscope before cell lysis in 1% Nonidet P-40 lysis buffer containing protease inhibitors as described previously (20). To measure the phosphorylation of ERK, 105 MDCK cells were plated on 60-mm dish in medium with 10% serum for 24 h and followed by a 24-h serum starvation. These cells were treated with 25 ng/ml HGF or 100 ng/ml EGF in serum-free medium for various times before cell lysis in 1% Nonidet P-40 lysis buffer containing protease inhibitors.

To express constitutively active MEK1, dominant negative MEK1, or HVH2, MDCK cells were grown on 60-mm dishes and co-transfected with pSV2neo and a plasmid encoding constitutively active MEK1, dominant negative MEK1, or HVH2 in 1:20 ratio using LipofectAMINE Plus according to the manufacturer's instructions. 24 h later, the medium was replaced with the fresh medium with 10% serum supplemented with 0.5 mg/ml neomycin G418. 7 days later, the neomycin-resistant cells were serum-staved and treated with or without 25 ng/ml HGF. 12 h later, the cells were lysed and subjected to immunoblotting analysis for MEK expression, ERK phosphorylation, and integrin alpha 2 expression.

Biotinylation and Immunoblotting-- For cell surface biotinylation, MDCK cells were grown for 2 days to allow cell colony formation. After washed in phosphate-buffered saline (PBS), cells were incubated in PBS containing 500 µg/ml sulfo-NHS-biotin at room temperature for 30 min, washed once with cold PBS, and incubated in PBS containing 0.1 M glycine (pH 7.4) on ice for 15 min. After several washes in PBS, the cells were lysed in Nonidet P-40 lysis buffer containing protease inhibitors. Aliquots (500 µg) of lysates were incubated with avidin-immobilized agarose beads for 1 h at 4 °C. After being washed three times in Nonidet P-40 lysis buffer, the beads were subjected to immunoblotting with polyclonal anti-integrin alpha 2.

For immunoblotting, whole cell lysates or avidin-precipitated complexes were boiled for 3 min in SDS sample buffer, subjected to SDS-polyacrylamide gel electrophoresis, and transferred to nitrocellulose (Schleicher & Schuell). Immunoblotting was performed with anti-integrin alpha 2 (1:1500), anti-integrin beta 1 (1:1500), anti-ERK (1:1500), or anti-phosphoERK (1:1500) using the PerkinElmer Life Sciences chemiluminescence system for detection.

Antibody Inhibition of HGF-induced Cell Scatter and Cell Migration-- MDCK cells were allowed to grow as discrete colonies on 60-mm dishes and then treated with 25 ng/ml HGF in the presence or the absence of 25 µg/ml monoclonal anti-integrin alpha 2 (clone P1E6). 12 h later, cells were washed in PBS, fixed in methanol for 10 min, and stained by modified Giemsa stain (Sigma) for 1 h. The percentage of scattered cells was measured in the total number of counted (~1000) cells from 50 colonies under a light microscope. A cell was judged as a scattered cell when it has lost contact with its neighbors and exhibited a fibroblast-like phenotype.

For the cell migration assay, the MDCK cells were treated with 25 ng/ml HGF for 12 h, collected by trypsinization, and suspended in serum-free medium at 5 × 105 cells/ml with or without 25 µg/ml monoclonal anti-integrin alpha 2 (P1E6) antibody. The cells were incubated with the antibody at 37 °C for 30 min before loading them to a Neuro Probe 48-well chemotaxis chamber (Cabin John, MD). Cells in the upper chamber were allowed to migrate through a porous (8-µm pore size) membrane toward the lower chamber containing 10 µg/ml collagen as an attractant for 5 h. The migrated cells were fixed, stained, and enumerated as described previously (21).

Northern Hybridization-- The total cellular RNA from MDCK cells that had been treated with or without 25 ng/ml HGF for 12 h was extracted by TRIzol reagent (Life Technologies, Inc.) following the manufacturer's instructions. To analyze the mRNA level of integrin alpha 2 in MDCK cells, an equal amount (25 µg) of total cellular RNA was fractionated through 1% agarose gels containing 2.2 M formaldehyde and transferred to nitrocellulose membrane (Schleicher & Schuell). A fluorescein-labeled DNA probe from human integrin alpha 2 was prepared using Renaissance random primer fluorescein labeling kit (PerkinElmer Life Sciences). The hybridization was carried out at 55 °C. After several washes, the membrane was incubated with peroxidase-conjugated anti-fluorescein (1:1000) at room temperature for 1 h, and the PerkinElmer Life Sciences chemiluminescence system was used for detection.

Immunofluorescence and Nuclear Staining-- MDCK cells (104) were grown on glass coverslips in 24-well plates for 2 days to allow cell colony formation. After an 18-h serum starvation, the cells were treated with HGF or EGF in serum-free medium for 15 min or 6 h, fixed with 4% paraformaldehyde at room temperature for 20 min, and permeabilized for 1 h by several changes of PBS containing 0.5% Triton X-100. For ERK staining, the cells were incubated with polyclonal anti-ERK (1:200 dilution in PBS) for 1 h at room temperature. After washed in PBS, the cells were incubated with fluorescein isothiocyanate-conjugated secondary antibody for 1 h. For nuclear staining, the cells were incubated with 0.5 µg/ml Hoechst 33258 (Sigma) for 10 min at room temperature. Preparations were then washed in PBS, mounted in anti-fading solution (20 mM n-propyl gallate in 80% glycerol), and analyzed by an immunofluorescent microscopy (Leica).

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

To characterize the induction of integrin alpha 2 expression by HGF, MDCK cells were allowed to grow as discrete colonies and then exposed to 25 ng/ml HGF for various times before harvest. Coincident with the scatter of cell colonies (Fig. 1B), the levels of integrins alpha 2 and beta 1 were gradually increased and reached 3.9- and 3.3-fold, respectively, 24 h after HGF stimulation (Fig. 1A). In contrast, the level of focal adhesion kinase, a key intracellular mediator in integrin signaling, was not affected by HGF stimulation. To measure the level of integrin alpha 2 on cell surface, cell surface proteins were biotinylated, precipitated by avidin-immobilized agarose beads, and immunoblotted with anti-integrin alpha 2 (Fig. 1C). Consistent with its increase in whole cell lysates, integrin alpha 2 on cell surface was also increased by HGF stimulation (25 ng/ml) and remained constant for 48 h. However, HGF at a low concentration (5 ng/ml) appeared to fail to promote the expression of integrin alpha 2 on the cell surface. To examine whether the HGF induction of integrin alpha 2 expression is regulated at transcriptional level, total RNA extracted from MDCK cells was analyzed by Northern hybridization using human integrin alpha 2 cDNA as a probe (Fig. 1D). The result showed that a 12-h treatment of HGF apparently (~3-fold) increased the level of integrin alpha 2 transcripts, indicating that the promoter activation of the integrin alpha 2 gene is involved in its increased expression induced by HGF.


View larger version (57K):
[in this window]
[in a new window]
 
Fig. 1.   Induction of integrin alpha 2beta 1 expression and cell scattering by HGF. A, MDCK cells were allowed to grow as colonies and incubated with 25 ng/ml HGF for various times as indicated. Whole cell lysates were prepared and analyzed by immunoblotting with anti-integrin alpha 2, anti-integrin beta 1, or anti-focal adhesion kinase (FAK). Quantification of protein expression was carried out by a densitometer, which is expressed as -fold increase relative to the level of cells without HGF treatment. B, the scatter of MDCK cell colonies upon 25 ng/ml HGF stimulation was chased under the same microscopic field and photographed at the indicated times. C, MDCK cells were incubated with 25 ng/ml HGF for various times or incubated with HGF at various concentrations for 24 h and then subjected to cell surface biotinylation, as described under "Experimental Procedures." Cell lysates were prepared and incubated with avidin-immobilized agarose beads. Integrin alpha 2 in avidin-precipitated complexes was detected by immunoblotting with anti-integrin alpha 2. Values are expressed as -fold increase relative to the level of cells without HGF stimulation. D, MDCK cell colonies were incubated with (+) or without (-) 25 ng/ml HGF for 12 h. Total cellular RNA was extracted and analyzed by Northern hybridization using human integrin alpha 2 cDNA as a probe. Ethidium bromide-stained agarose gel was shown to indicate an equal loading of total RNA. The positions of the 28 and 18 S ribosomal RNAs are indicated. The values are expressed as -fold increase relative to the level of cells without HGF stimulation.

To examine the role of de novo synthesized integrin alpha 2beta 1 in HGF-induced cell scattering, a functional blocking antibody against integrin alpha 2 was applied in cell scatter assays (Fig. 2A). We quantified the extent of cell scattering by counting the number of cells that have lost contact with their neighbors in a total of 50 colonies containing ~1000 cells. Our results indicated that the HGF-induced cell scattering was partially (~40%) inhibited by the integrin alpha 2 blocking antibody at the concentration of 25 µg/ml. However, at the same concentration, this antibody was able to efficiently inhibit HGF-induced cell migration toward collagen in a chemotaxis chamber (Fig. 2B), indicating a successful inhibition of integrin alpha 2 function by this antibody. Thus, these results indicated that increased expression of integrin alpha 2 induced by HGF contributes only partially to cell scattering.


View larger version (23K):
[in this window]
[in a new window]
 
Fig. 2.   Inhibition of HGF-induced cell scattering and transwell migration by function blocking antibody against integrin alpha 2. A, MDCK cells were incubated with 25 ng/ml HGF in the presence (+) or the absence (-) of the functional blocking antibody against integrin alpha 2 at the concentration 25 µg/ml. Rabbit anti-mouse IgG was used as a control antibody at the same concentration. 12 h later, the cells were fixed and stained, and the percentage of scattered cells in total counted (~1000) cells from 50 colonies was measured. A cell was judged as a scattered cell when it lost contact with its neighbors and exhibited a fibroblast-like phenotype. The values (means ± S.E.) are from three separate experiments. Relative cell scattering was calculated based on the level of cell scattering in the absence of antibody. B, MDCK cells were incubated with (+) or without (-) 25 ng/ml HGF for 12 h before subjecting to cell migration assays. The cells in the upper half of the chamber with (+) or without (-) the functional blocking antibody against integrin alpha 2 (25 µg/ml) or rabbit anti-mouse IgG (25 µg/ml) were allowed to migrate through a porous membrane toward the lower chamber as described under "Experimental Procedures." The values (means ± S.E.) are from 12 fields and three separate experiments. The relative cell migration was calculated based on the level of cell migration without treatments of HGF and the antibody.

PMA, a strong activator for conventional and novel subgroups of protein kinase C (PKC), has previously been shown to induce integrin alpha 2 expression in osteosarcoma cells (22) and breast cancer cells (23). To examine whether PKC mediates the effect of HGF on integrin alpha 2 induction and cell scattering, MDCK cells were treated with HGF or PMA in the presence of a broad range PKC inhibitor, bisindolylmaleimide. As shown in Fig. 3A, the effect of PMA on promoting both integrin alpha 2 expression and cell scattering was significantly inhibited by bisindolylmaleimide, supporting an essential role for PKC in PMA-induced cellular effects. In contrast, bisindolylmaleimide did not appear to inhibit HGF-induced cell scattering and only modestly (~25%) decreased the level of integrin alpha 2 induced by HGF, indicating that the effect of HGF on promoting integrin alpha 2 expression and cell scattering is mainly PKC-independent.


View larger version (72K):
[in this window]
[in a new window]
 
Fig. 3.   Effect of various inhibitors on integrin alpha 2 expression and cell scattering induced by HGF. A, MDCK cell colonies remained untreated (control) or treated with 25 ng/ml HGF or 100 nM PMA in the presence (+) or absence (-) of 1 µM of the broad range PKC inhibitor bisindolylmaleimide (Bis.). 24 h later, the micrographs were taken before cell lysis, and integrin alpha 2 in whole cell lysates was detected by immunoblotting with anti-integrin alpha 2. The values are expressed as -fold increase relative to the level in control cells. B, MDCK cells were incubated with 25 ng/ml HGF in the presence of 100 µM genistein (a general tyrosine kinase inhibitor), 10 µM PP1 (a selective Src family kinase inhibitor), 100 µM PD98059 (a specific MEK inhibitor), 25 µM LY294002 (a specific PI3K inhibitor), 10 µg/ml cycloheximide (CHX; a selective translation inhibitor), or control solvent Me2SO (DMSO). 24 h later, the micrographs were taken before cell lysis, and integrin alpha 2 in whole cell lysates was detected by immunoblotting with anti-integrin alpha 2. The values are expressed as -fold increase relative to the level in control cells without treatment of HGF and inhibitors.

To identify signal transduction pathways required for HGF to induce integrin alpha 2 expression, inhibitors including genistein (a general tyrosine kinase inhibitor), PP1 (a selective Src family kinase inhibitor), PD98059 (a specific MEK inhibitor), LY294002 (a specific PI3K inhibitor), and cycloheximide (a translation inhibitor) were applied to the experiments (Fig. 3B). Of these inhibitors, genistein, PD98059, and cycloheximide were found to efficiently inhibit the effect of HGF on integrin alpha 2 induction. In contrast, PP1 and LY294002 had no such effect. These results indicate that MEK, but not Src or PI3K, is required for HGF to induce integrin alpha 2 expression. It should be noted that in the presence of PP1 or LY294002, although cells retained their response to HGF for increasing integrin alpha 2 expression, they failed to scatter, indicating that the elevated expression of integrin alpha 2 alone is not sufficient for cell scattering.

As suggested in Fig. 3, the HGF induction of integrin alpha 2 expression is mainly dependent on the MEK pathway. However, in addition to HGF, many other growth factors such as EGF are known to potently activate MEK and its downstream targets, ERK 1 and 2. To examine whether EGF induces integrin alpha 2 expression and/or cell scattering, MDCK cells were incubated with EGF or HGF for 24 h. As shown in Fig. 4A, although EGF induced a slight increase in integrin alpha 2 expression and lamellipodium formation around cell colony, it failed to trigger cell scattering. Next, we measured the phosphorylation of ERK upon HGF or EGF stimulation, which serves as an indicator for ERK activation (Fig. 4B). The phosphorylation of ERK induced by EGF was transient; it declined by 30 min and returned to the basal level by 1 h post-stimulation. In contrast, HGF induced a sustained phosphorylation of ERK, which lasted for at least 12 h post-stimulation. Furthermore, the sustained phosphorylation of ERK induced by HGF coincided with its persistent nuclear accumulation (Fig. 4C).


View larger version (76K):
[in this window]
[in a new window]
 
Fig. 4.   Sustained activation of ERK in MDCK cells stimulated by HGF correlates with its ability to induce integrin alpha 2 expression and cell scattering. A, MDCK cell colonies remained untreated (control) or treated with 25 ng/ml HGF or 100 ng/ml EGF. 24 h later, the micrographs were taken before cell lysis, and integrin alpha 2 in whole cell lysates was detected by immunoblotting with anti-integrin alpha 2. The values are expressed as -fold increase relative to the level in control cells. B, cell colonies remained untreated (lane 0) or were treated with 25 ng/ml HGF (lanes H) or 100 ng/ml EGF (lanes E) for various times as indicated. An equal amount of cell lysates was analyzed by immunoblotting with anti-phosphoERK or anti-ERK. C, cell colonies remained untreated (control) or treated with 25 ng/ml HGF or 100 ng/ml EGF for 15 min or 6 h. After fixation and Triton X-100 permeabilization, cells were stained for ERK with anti-ERK and for nucleus with Hoechst 33258 (DAPI) and visualized by fluorescent microscope.

To further examine whether sustained activation of ERK leads to integrin alpha 2 expression, constitutively active MEK was expressed in MDCK cells (Fig. 5A). As expected, the expression of constitutively active MEK resulted in ERK activation, and importantly, even in the absence of HGF stimulation, it enhanced the expression of integrin alpha 2. Conversely, the expression of an ERK phosphatase HVH2 or a dominant negative MEK suppressed both HGF-induced ERK activation and integrin alpha 2 expression (Fig. 5B). These results together suggest that sustained activation of the MEK/ERK signal cascade may be required and sufficient for induction of integrin alpha 2 expression.


View larger version (45K):
[in this window]
[in a new window]
 
Fig. 5.   Induction of integrin alpha 2 expression by HGF requires MEK and ERK. A, MDCK cells were transfected with empty vector (control) or constitutively active MEK (C.A. MEK) and selected in neomycin. The pool of neomycin-resistant cells were serum-starved and treated with (+) or without (-) HGF for 12 h. Cell lysates were prepared and analyzed by immunoblotting with anti-integrin alpha 2, anti-MEK, anti-phosphoERK, or anti-ERK. The values are expressed as -fold increase relative to integrin alpha 2 in control cells without HGF stimulation. B, MDCK cells were transfected with empty vector (control), HVH2 (an ERK phosphatase), or dominant negative MEK (D.N. MEK) and selected in neomycin. The pool of neomycin-resistant cells were serum-starved and treated with (+) or without (-) HGF for 12 h. Cell lysates were prepared and analyzed by immunoblotting with anti-integrin alpha 2, anti-phosphoERK, or anti-ERK. The values are expressed as -fold increase relative to the level in control cells without HGF stimulation.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

In this study, we have used MDCK cells as a model to investigate the role of up-regulation of integrin alpha 2beta 1 in HGF-induced cell scattering and the signal transduction pathways responsible for this up-regulation. We showed that the level of integrin alpha 2beta 1 expression increased by HGF stimulation correlated with the extent of cell scattering (Fig. 1) and that block of HGF-induced integrin alpha 2 expression by inhibitors including genistein, PD98059, and cycloheximide all accompanied an inhibition in cell scattering (Fig. 3B). However, only 40% of HGF-induced cell scattering could be inhibited by the functional blocking antibody against integrin alpha 2 (Fig. 2A), suggesting that increased integrin alpha 2beta 1 may contribute only partially to cell scattering likely through promoting the third phase of cell scattering (i.e. cell migration). In addition, our results presented here also suggest that increased expression of integrin alpha 2 alone may not be sufficient for MDCK cells to scatter. We showed in Fig. 3B that in the presence of PP1 or LY294002, although cells retained their response to HGF for increasing integrin alpha 2 expression, they failed to scatter.

Although the ERK signaling pathway has been implicated to be essential for HGF-induced cell scattering (13-15), here we propose for the first time that the duration of MEK/ERK activation is likely to be the major determinant for cells to activate integrin alpha 2 expression and cell scattering upon HGF stimulation. Treatment of MDCK cells with HGF led to prolonged activation of ERK as judged by the phosphorylation of ERK and its accumulation in the nucleus (Fig. 4). In contrast, EGF, which does not cause MDCK cells to scatter, led to transient activation of ERK. Moreover, the expression of constitutively active MEK, which led to sustained activation of ERK, increased the expression of integrin alpha 2 even in the absence of HGF stimulation (Fig. 5A). In contrast, the expression of ERK phosphatase or dominant negative MEK blocked HGF-induced integrin alpha 2 expression (Fig. 5B). Together, these data support a model in which the different consequences of transient versus sustained activation of ERK are because sustained activation leads to persistent nuclear accumulation of ERK, resulting in phosphorylation of transcription factors and changes in gene expression.

We showed in Fig. 1 that the increased expression of integrin alpha 2 by HGF in MDCK cells was a consequence of increased alpha 2 mRNA likely because of transcriptional activation of the integrin alpha 2 gene. The mechanism of transcriptional regulation of the canine integrin alpha 2 gene by HGF is currently unknown. However, characterization of the 5'-flanking region of the human integrin alpha 2 gene revealed that the promoter region contains consensus binding sites for several transcription factors, including Sp1, AP1, and AP2 (24). The binding of phosphorylated Sp1 proteins to two Sp1-binding sites in the core promoter region of the human integrin alpha 2 gene has been shown to be required for full promoter activity (25). It is known that ERK activation increases AP1 activity via c-Jun activation and increased c-Fos synthesis, leading to an increase in c-Jun/c-Fos heterodimerization and DNA binding (26, 27). In addition, a recent study showed that ERK was able to phosphorylate Sp1 and induced its DNA binding activity (28). Therefore, it is possible that persistent nuclear accumulation of ERK induced by HGF stimulation may target Sp1 and AP1, leading to activation of the integrin alpha 2 gene. Furthermore, the MEK inhibitor PD98059 inhibits the up-regulation of integrin alpha 2 expression induced by PMA in MDCK cells (data not shown) or by phorbol dibutyrate in human leukemia K562 cells (29), suggesting that the MEK/ERK cascade may be generally required for extracellular stimuli to activate the integrin alpha 2 gene.

Although the role of the ERK singling pathway in cell proliferation has been well established (30, 31), increasing evidence has suggested that the duration of ERK activation may be a crucial determinant for cells to proceed certain cellular functions other than proliferation. For example, sustained ERK activity has been shown to be required for nerve growth factor-induced neuronal differentiation of the phaeochromocytoma PC12 cells (32), fibroblast growth factor-induced angiogenesis of the endothelial cells on chick chorioallantoic membrane (33), and PMA-induced macrophage-like differentiation of the myeloid leukemia TF-1a cells (34). In this study, we demonstrate that HGF-mediated sustained activation of ERK is required for MDCK cell scattering, associated with morphological transformation to a mesenchymal cell phenotype. The mechanism by which MDCK cells maintain ERK in an active status for a long period upon HGF stimulation is currently unclear. York et al. (32) showed that in PC12 cells, the early phase of nerve growth factor-stimulated ERK activation is mediated by the small GTPase Ras, but the sustained phase of the ERK activation is due to the activation of another small GTPase, Rap1. Thus, it will be of interest to examine whether Rap1 is involved in HGF-induced sustained activation of ERK. Alternatively, the de novo expression of integrin alpha 2beta 1 stimulated by HGF may contribute to the sustained phase of ERK activation. It is known that integrin-mediated cell adhesion to extracellular matrix proteins activates the ERK cascade and often potentiates the effect of growth factors on activating the cascade (35). Eliceiri et al. (33) showed that the sustained phase but not the initial phase of ERK activation by the fibroblast growth factor depends on integrin alpha vbeta 3 in endothelial cells. The potential role of de novo synthesized integrin alpha 2beta 1 in HGF-induced sustained activation of ERK cascade is currently under investigation.

It is known that in cells transformed by oncogenic Ras or Raf, the relative ability of external stimuli to activate ERK is usually diminished. However, we showed in this study that the expression of constitutively active MEK in MDCK cells weakly activated ERK compared with HGF and did not negatively impact on subsequent activation of ERK by HGF (Fig. 5A). The explanation for this discrepancy could be simply the low expression of constitutively active MEK in our selected MDCK cells, in which a fraction of ERK remains inactive and susceptible to HGF stimulation. This assumption was based on our observation that consecutive culture of active MEK-expressed MDCK cells, especially those with higher expression level of it, resulted in apoptosis.2 These results suggest that severely aberrant activation of ERK by constitutively active MEK may be cytotoxic to MDCK cells and that only those with a lower expression level of active MEK can survive. Alternatively, it is possible that in addition to the Ras/Raf/MEK pathway, other signal transduction pathways may collaborate to activate ERK upon HGF stimulation. For example, ERK has been shown to be activated by protein kinase C delta  and zeta  via Ras-independent pathways (36, 37) and inactivated by protein phosphatases such as PP2A (38) and ERK phosphatases (39) in other systems. Therefore, it is plausible that activation of protein kinase C and/or inactivation of ERK/MEK phosphatases by HGF may further activate ERK in MDCK cells expressing constitutively active MEK. Recently, the protein-tyrosine phosphatase SHP-2 was shown to be required for HGF-induced activation of ERK in MDCK cells (40), although the detailed mechanism is currently unclear.

In this study, we have found that PMA was able to induce the E-M transition similar to that induced by HGF (Fig. 3). However, unlike HGF, the effect of PMA on induction of the E-M transition is mainly PKC-dependent (Fig. 3). In addition, stable expression of constitutively active MEK in MDCK cells has been shown to lead to the E-M transition (41), suggesting that sustained activation of ERK signaling cascade may be sufficient for triggering this process. Zondag et al. (12) reported recently that expression of oncogenic Ras leads to the E-M transition of MDCK cells through regulating the balance between the activation state of two GTPase Rho family proteins, Rac and Rho. They showed that oncogenic Ras-mediated sustained ERK signaling decreases Rac activity through transcriptional down-regulation of the Rac-specific exchange factor Tiam1 and, by contrast, increases Rho activity through an unknown mechanism. It remains to be tested whether HGF, PMA, and constitutive active MEK act in the same fashion as oncogenic Ras to induce the E-M transition.

    ACKNOWLEDGEMENT

We thank Dr. K.-L. Guan for the plasmid encoding constitutively active MEK, dominant negative MEK, and phosphatase HVH2.

    FOOTNOTES

* This work was supported by National Science Council, Taiwan Grant NSC90-2311-B-005-063 (to H.-C. C.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger To whom correspondence should be addressed. Tel.: 886-4-22854922; Fax: 886-4-22851797; E-mail: hcchen@nchu.edu.tw.

Published, JBC Papers in Press, April 3, 2001, DOI 10.1074/jbc.M010669200

2 C.-C. Liang and H.-C. Chen, unpublished data.

    ABBREVIATIONS

The abbreviations used are: HGF, hepatocyte growth factor; E-M, epithelial-mesenchymal; MDCK, Madin-Darby canine kidney; PI3K, phosphatidylinositol 3-kinase; ERK, extracellular signal-regulated kinase; MEK, ERK kinase; EGF, epidermal growth factor; PMA, phorbol-12-myristate-13-acetate; PBS, phosphate-buffered saline; PKC, protein kinase C.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Zarnegar, R., and Michalopoulos, G. K. (1995) J. Cell Biol. 129, 1177-1180[Medline] [Order article via Infotrieve]
2. Bottaro, D. P., Rubin, J. S., Faletto, D. L., Chan, A. M.-L., Kmiecik, T. E., Vande Woulde, G. F., and Aaronson, S. A. (1991) Science 251, 802-804[Medline] [Order article via Infotrieve]
3. Naldini, L., Vigna, E., Ferracini, R., Longati, P., Gandino, L., Prat, M., and Comoglio, P. M. (1991) Mol. Cell. Biol. 11, 1793-1803[Medline] [Order article via Infotrieve]
4. Ridley, A. J., Comoglio, P. M., and Hall, A. (1995) Mol. Cell. Biol. 15, 1110-1122[Abstract]
5. Royal, I., and Park, M. (1995) J. Biol. Chem. 270, 27780-27787[Abstract/Free Full Text]
6. Sander, E. E., van Delft, S., ten Klooster, J. P., Reid, T., van der Kammen, R. A., Michiels, F., and Collard, J. G. (1998) J. Cell Biol. 143, 1385-1398[Abstract/Free Full Text]
7. Lai, J.-F., Kao, S.-C., Jiang, S.-T., Tang, M.-J., Chan, P.-C., and Chen, H.-C. (2000) J. Biol. Chem. 275, 7474-7480[Abstract/Free Full Text]
8. Hartmann, G., Weidner, K. M., Schwarz, H., and Birchmeier, W. (1994) J. Biol. Chem. 269, 21936-21939[Abstract/Free Full Text]
9. Rodriguez-Viciana, P., Warne, P. H., Dhand, R., Vanhaesebroeck, B., Gout, I., Fry, M. J., Waterfield, M. D., and Downward, J. (1994) Nature 370, 527-532[CrossRef][Medline] [Order article via Infotrieve]
10. Hu, Q., Klippel, A., Muslin, A. J., Fantl, W. J., and Williams, L. T. (1995) Science 268, 100-102[Medline] [Order article via Infotrieve]
11. Potempa, S., and Ridley, A. J. (1998) Mol. Biol. Cell 9, 2185-2200[Abstract/Free Full Text]
12. Zondag, G. C. M., Evers, E. E., ten Klooster, J. P., Janssen, L., van der Kammen, R. A., and Collard, J. G. (2000) J. Cell Biol. 149, 775-781[Abstract/Free Full Text]
13. Terauchi, R., and Kitamura, N. (2000) Exp. Cell Res. 256, 411-422[CrossRef][Medline] [Order article via Infotrieve]
14. Khwaja, A., Lehmann, K., Marte, B. M., and Downward, J. (1998) J. Biol. Chem. 273, 18793-18801[Abstract/Free Full Text]
15. Herrera, R. (1998) J. Cell Sci. 111, 1039-1049[Abstract/Free Full Text]
16. Schoenenberger, C.-A., Zuk, A., Zinkl, G. M., Kendall, D., and Matlin, K. S. (1994) J. Cell Sci. 107, 527-541[Abstract/Free Full Text]
17. Saelman, E. U., Keely, P. J., and Santoro, S. A. (1995) J. Cell Sci. 108, 3531-3540[Abstract/Free Full Text]
18. Sugimoto, T., Stewart, S., Han, M., and Guan, K.-L. (1998) EMBO J. 17, 1717-1727[Abstract/Free Full Text]
19. Guan, K.-L., and Butch, E. (1995) J. Biol. Chem. 270, 7191-7203
20. Chen, H.-C., Chan, P.-C., Tang, M.-J., Cheng, C.-H., and Chang, T.-J. (1998) J. Biol. Chem. 273, 25777-25782[Abstract/Free Full Text]
21. Reiske, H. R., Kao, S.-C., Cary, L. A., Guan, J.-L., Lai, J.-F., and Chen, H.-C. (1999) J. Biol. Chem. 274, 12361-12366[Abstract/Free Full Text]
22. Nissinen, L., Westermarck, J., Koivisto, L., Kahari, V.-M., and Heino, J. (1998) Exp. Cell Res. 243, 1-10[CrossRef][Medline] [Order article via Infotrieve]
23. Rosfjord, E. C., Maemura, M., Johnson, M. D., Torri, J. A., Akiyama, S. K., Woods, V. L., and Dickson, R. B. (1999) Exp. Cell Res. 248, 260-271[CrossRef][Medline] [Order article via Infotrieve]
24. Zutter, M. M., Santoro, S. A., Painter, A. S., Tsung, Y. L., and Gafford, A. (1994) J. Biol. Chem. 269, 463-469[Abstract/Free Full Text]
25. Zutter, M. M., Ryan, E. E., and Painter, A. D. (1997) Blood 90, 678-689[Abstract/Free Full Text]
26. Angel, P., Hattori, K., Smeal, T., and Karin, M. (1988) Cell 55, 875-885[Medline] [Order article via Infotrieve]
27. Chiu, R., Boyle, W. J., Meek, J., Smeal, T., Hunter, T., and Karin, M. (1988) Cell 54, 541-552[Medline] [Order article via Infotrieve]
28. Merchant, J. L., Du, M., and Todisco, A. (1999) Biochem. Biophys. Res. Commun. 254, 454-461[CrossRef][Medline] [Order article via Infotrieve]
29. Zutter, M. M., Painter, A. D., and Yang, X. (1999) Blood 93, 1600-1611[Abstract/Free Full Text]
30. Pages, G., Lenormand, P., Allemain, G. L., Chambard, J. C., Meloche, S., and Pouyssegur, J. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 8319-8323[Abstract/Free Full Text]
31. Seger, R., and Krebs, E. G. (1995) FASEB J. 9, 726-735[Abstract/Free Full Text]
32. York, R. D., Yao, H., Dillon, T., Ellig, C. L., Eckert, S. P., McCleskey, E. W., and Stork, P. J. S. (1998) Nature 392, 622-626[CrossRef][Medline] [Order article via Infotrieve]
33. Eliceiri, B., Klemke, R., Stromblad, S., and Cheresh, D. A. (1998) J. Cell Biol. 140, 1255-1263[Abstract/Free Full Text]
34. Hu, X., Moscinski, L. C., Valkov, N. I., Fisher, A. B., Hill, B. J., and Zuckerman, K. S. (2000) Cell Growth Differ. 11, 191-200[Abstract/Free Full Text]
35. Howe, A. K., and Juliano, R. L. (1998) J. Biol. Chem. 273, 27268-27274[Abstract/Free Full Text]
36. Ueda, Y., Hirai, S., Osada, S., Suzuki, A., Mizuno, K., and Ohno, S. (1996) J. Biol. Chem. 271, 23512-23519[Abstract/Free Full Text]
37. Takeda, H., Matozaki, T., Takada, T., Noguchi, T., Yamao, T., Tsuda, M., Ochi, F., Fukunaga, K., Inagaki, K., and Kasuga, M. (1999) EMBO J. 18, 386-395[Abstract/Free Full Text]
38. Alessi, D. R., Gomez, N., Moorhead, G., Lewis, T., Keyse, S. M., and Cohen, P. (1995) Curr. Biol. 5, 283-295[Medline] [Order article via Infotrieve]
39. Muda, M., Boschert, U., Dickinson, R., Martinou, J.-C., Martinou, I., Camps, M., Schlegel, W., and Arkinstall, S. (1996) J. Biol. Chem. 271, 4319-4326[Abstract/Free Full Text]
40. Maroun, C. R., Naujokas, M. A., Holgado-Madruga, M., Wong, A. J., and Park, M. (2000) Mol. Cell. Biol. 20, 8513-8525[Abstract/Free Full Text]
41. Schramek, H., Feifel, E., Healy, E., and Pollack, V. (1997) J. Biol. Chem. 272, 11426-11433[Abstract/Free Full Text]


Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.